Capecitabine/Cyclophosphamide - Sanofi

Drug Profile

Capecitabine/Cyclophosphamide - Sanofi

Alternative Names: Cyclophosphamide/Capecitabine - Sanofi

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Carbamates; Cyclophosphamides; Myeloablative agonists; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Alkylating agents; Immunomodulators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 05 Feb 2016 Preclinical trials in Breast cancer in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top